##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	203	203	.	+	.	ID=ID_0;Name=g.C-63T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C-63T;aa_name=;hgvs_nt=NC_045512.2:g.63C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	222	222	.	+	.	ID=ID_1;Name=g.C-44T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C-44T;aa_name=;hgvs_nt=NC_045512.2:g.44C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_2;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	497	497	.	+	.	ID=ID_3;Name=T78A;alias=T78A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A232G;aa_name=p.T78A;hgvs_nt=NC_045512.2:g.232A>G;hgvs_aa=YP_009724389.1:p.Thr78Ala;hgvs_alias=YP_009724389.1:Thr78Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	548	548	.	+	.	ID=ID_4;Name=I95V;alias=I95V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A283G;aa_name=p.I95V;hgvs_nt=NC_045512.2:g.283A>G;hgvs_aa=YP_009724389.1:p.Ile95Val;hgvs_alias=YP_009724389.1:Ile95Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	583	583	.	+	.	ID=ID_5;Name=V106V;alias=V106V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C318T;aa_name=p.V106V;hgvs_nt=NC_045512.2:g.318C>T;hgvs_aa=YP_009724389.1:p.Val106Val;hgvs_alias=YP_009724389.1:Val106Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	712	712	.	+	.	ID=ID_6;Name=L149L;alias=L149L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=225;ao=21;dp=246;sample_size=288;Reference_seq=T;Variant_seq=A;nt_name=g.T447A;aa_name=p.L149L;hgvs_nt=NC_045512.2:g.447T>A;hgvs_aa=YP_009724389.1:p.Leu149Leu;hgvs_alias=YP_009724389.1:Leu149Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08536585365853659;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	733	733	.	+	.	ID=ID_7;Name=D156D;alias=D156D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T468C;aa_name=p.D156D;hgvs_nt=NC_045512.2:g.468T>C;hgvs_aa=YP_009724389.1:p.Asp156Asp;hgvs_alias=YP_009724389.1:Asp156Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	829	829	.	+	.	ID=ID_8;Name=N188N;alias=N8N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C564T;aa_name=p.N188N;hgvs_nt=NC_045512.2:g.564C>T;hgvs_aa=YP_009724389.1:p.Asn188Asn;hgvs_alias=YP_009724389.1:Asn8Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1002	1002	.	+	.	ID=ID_9;Name=E246A;alias=E66A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=237;ao=9;dp=246;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A737C;aa_name=p.E246A;hgvs_nt=NC_045512.2:g.737A>C;hgvs_aa=YP_009724389.1:p.Glu246Ala;hgvs_alias=YP_009724389.1:Glu66Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.036585365853658534;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1150	1150	.	+	.	ID=ID_10;Name=G295G;alias=G115G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C885T;aa_name=p.G295G;hgvs_nt=NC_045512.2:g.885C>T;hgvs_aa=YP_009724389.1:p.Gly295Gly;hgvs_alias=YP_009724389.1:Gly115Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1190	1190	.	+	.	ID=ID_11;Name=P309S;alias=P129S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=240;ao=6;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C925T;aa_name=p.P309S;hgvs_nt=NC_045512.2:g.925C>T;hgvs_aa=YP_009724389.1:p.Pro309Ser;hgvs_alias=YP_009724389.1:Pro129Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1361	1361	.	+	.	ID=ID_12;Name=V366F;alias=V186F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1096T;aa_name=p.V366F;hgvs_nt=NC_045512.2:g.1096G>T;hgvs_aa=YP_009724389.1:p.Val366Phe;hgvs_alias=YP_009724389.1:Val186Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1722	1722	.	+	.	ID=ID_13;Name=A486V;alias=A306V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1457T;aa_name=p.A486V;hgvs_nt=NC_045512.2:g.1457C>T;hgvs_aa=YP_009724389.1:p.Ala486Val;hgvs_alias=YP_009724389.1:Ala306Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1825	1825	.	+	.	ID=ID_14;Name=A520A;alias=A340A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1560T;aa_name=p.A520A;hgvs_nt=NC_045512.2:g.1560C>T;hgvs_aa=YP_009724389.1:p.Ala520Ala;hgvs_alias=YP_009724389.1:Ala340Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1878	1878	.	+	.	ID=ID_15;Name=S538L;alias=S358L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=240;ao=6;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1613T;aa_name=p.S538L;hgvs_nt=NC_045512.2:g.1613C>T;hgvs_aa=YP_009724389.1:p.Ser538Leu;hgvs_alias=YP_009724389.1:Ser358Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1960	1960	.	+	.	ID=ID_16;Name=A565A;alias=A385A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1695T;aa_name=p.A565A;hgvs_nt=NC_045512.2:g.1695C>T;hgvs_aa=YP_009724389.1:p.Ala565Ala;hgvs_alias=YP_009724389.1:Ala385Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2110	2110	.	+	.	ID=ID_17;Name=N615N;alias=N435N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=235;ao=10;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1845T;aa_name=p.N615N;hgvs_nt=NC_045512.2:g.1845C>T;hgvs_aa=YP_009724389.1:p.Asn615Asn;hgvs_alias=YP_009724389.1:Asn435Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04081632653061224;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2358	2358	.	+	.	ID=ID_18;Name=A698V;alias=A518V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2093T;aa_name=p.A698V;hgvs_nt=NC_045512.2:g.2093C>T;hgvs_aa=YP_009724389.1:p.Ala698Val;hgvs_alias=YP_009724389.1:Ala518Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2455	2455	.	+	.	ID=ID_19;Name=L730L;alias=L550L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=228;ao=18;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2190T;aa_name=p.L730L;hgvs_nt=NC_045512.2:g.2190C>T;hgvs_aa=YP_009724389.1:p.Leu730Leu;hgvs_alias=YP_009724389.1:Leu550Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07317073170731707;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2749	2749	.	+	.	ID=ID_20;Name=D828D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=3;ao=243;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2484T;aa_name=p.D828D;hgvs_nt=NC_045512.2:g.2484C>T;hgvs_aa=YP_009724389.1:p.Asp828Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9878048780487805;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2764	2764	.	+	.	ID=ID_21;Name=V833V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G2499T;aa_name=p.V833V;hgvs_nt=NC_045512.2:g.2499G>T;hgvs_aa=YP_009724389.1:p.Val833Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_22;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3117	3117	.	+	.	ID=ID_23;Name=T951I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2852T;aa_name=p.T951I;hgvs_nt=NC_045512.2:g.2852C>T;hgvs_aa=YP_009724389.1:p.Thr951Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3140	3140	.	+	.	ID=ID_24;Name=P959S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=232;ao=14;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2875T;aa_name=p.P959S;hgvs_nt=NC_045512.2:g.2875C>T;hgvs_aa=YP_009724389.1:p.Pro959Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.056910569105691054;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3275	3275	.	+	.	ID=ID_25;Name=T1004A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A3010G;aa_name=p.T1004A;hgvs_nt=NC_045512.2:g.3010A>G;hgvs_aa=YP_009724389.1:p.Thr1004Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3532	3532	.	+	.	ID=ID_26;Name=D1089D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=106;ao=1;dp=107;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T3267C;aa_name=p.D1089D;hgvs_nt=NC_045512.2:g.3267T>C;hgvs_aa=YP_009724389.1:p.Asp1089Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009345794392523364;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3602	3602	.	+	.	ID=ID_27;Name=H1113Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=107;ao=2;dp=109;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3337T;aa_name=p.H1113Y;hgvs_nt=NC_045512.2:g.3337C>T;hgvs_aa=YP_009724389.1:p.His1113Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01834862385321101;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3634	3634	.	+	.	ID=ID_28;Name=N1123N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=109;ao=1;dp=110;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3369T;aa_name=p.N1123N;hgvs_nt=NC_045512.2:g.3369C>T;hgvs_aa=YP_009724389.1:p.Asn1123Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00909090909090909;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3828	3828	.	+	.	ID=ID_29;Name=S1188L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3563T;aa_name=p.S1188L;hgvs_nt=NC_045512.2:g.3563C>T;hgvs_aa=YP_009724389.1:p.Ser1188Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3992	3992	.	+	.	ID=ID_30;Name=L1243L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3727T;aa_name=p.L1243L;hgvs_nt=NC_045512.2:g.3727C>T;hgvs_aa=YP_009724389.1:p.Leu1243Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4276	4276	.	+	.	ID=ID_31;Name=Y1337Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C4011T;aa_name=p.Y1337Y;hgvs_nt=NC_045512.2:g.4011C>T;hgvs_aa=YP_009724389.1:p.Tyr1337Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4504	4504	.	+	.	ID=ID_32;Name=E1413D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G4239T;aa_name=p.E1413D;hgvs_nt=NC_045512.2:g.4239G>T;hgvs_aa=YP_009724389.1:p.Glu1413Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4832	4832	.	+	.	ID=ID_33;Name=L1523I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C4567A;aa_name=p.L1523I;hgvs_nt=NC_045512.2:g.4567C>A;hgvs_aa=YP_009724389.1:p.Leu1523Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4911	4911	.	+	.	ID=ID_34;Name=E1549G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A4646G;aa_name=p.E1549G;hgvs_nt=NC_045512.2:g.4646A>G;hgvs_aa=YP_009724389.1:p.Glu1549Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4999	4999	.	+	.	ID=ID_35;Name=N1578N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=238;ao=4;dp=242;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C4734T;aa_name=p.N1578N;hgvs_nt=NC_045512.2:g.4734C>T;hgvs_aa=YP_009724389.1:p.Asn1578Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01652892561983471;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5007	5007	.	+	.	ID=ID_36;Name=T1581M;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=240;ao=2;dp=242;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C4742T;aa_name=p.T1581M;hgvs_nt=NC_045512.2:g.4742C>T;hgvs_aa=YP_009724389.1:p.Thr1581Met;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008264462809917356;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5497	5497	.	+	.	ID=ID_37;Name=C1744C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=225;ao=21;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C5232T;aa_name=p.C1744C;hgvs_nt=NC_045512.2:g.5232C>T;hgvs_aa=YP_009724389.1:p.Cys1744Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08536585365853659;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5648	5648	.	+	.	ID=ID_38;Name=K1795Q;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A5383C;aa_name=p.K1795Q;hgvs_nt=NC_045512.2:g.5383A>C;hgvs_aa=YP_009724389.1:p.Lys1795Gln;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5787	5787	.	+	.	ID=ID_39;Name=S1841F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C5522T;aa_name=p.S1841F;hgvs_nt=NC_045512.2:g.5522C>T;hgvs_aa=YP_009724389.1:p.Ser1841Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5800	5800	.	+	.	ID=ID_40;Name=L1845L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G5535A;aa_name=p.L1845L;hgvs_nt=NC_045512.2:g.5535G>A;hgvs_aa=YP_009724389.1:p.Leu1845Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5822	5822	.	+	.	ID=ID_41;Name=L1853F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=228;ao=18;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C5557T;aa_name=p.L1853F;hgvs_nt=NC_045512.2:g.5557C>T;hgvs_aa=YP_009724389.1:p.Leu1853Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07317073170731707;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6040	6040	.	+	.	ID=ID_42;Name=F1925F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C5775T;aa_name=p.F1925F;hgvs_nt=NC_045512.2:g.5775C>T;hgvs_aa=YP_009724389.1:p.Phe1925Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6266	6266	.	+	.	ID=ID_43;Name=A2001T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G6001A;aa_name=p.A2001T;hgvs_nt=NC_045512.2:g.6001G>A;hgvs_aa=YP_009724389.1:p.Ala2001Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6319	6319	.	+	.	ID=ID_44;Name=P2018P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A6054G;aa_name=p.P2018P;hgvs_nt=NC_045512.2:g.6054A>G;hgvs_aa=YP_009724389.1:p.Pro2018Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6428	6428	.	+	.	ID=ID_45;Name=P2055S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6163T;aa_name=p.P2055S;hgvs_nt=NC_045512.2:g.6163C>T;hgvs_aa=YP_009724389.1:p.Pro2055Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6471	6471	.	+	.	ID=ID_46;Name=T2069I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6206T;aa_name=p.T2069I;hgvs_nt=NC_045512.2:g.6206C>T;hgvs_aa=YP_009724389.1:p.Thr2069Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6476	6476	.	+	.	ID=ID_47;Name=V2071F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G6211T;aa_name=p.V2071F;hgvs_nt=NC_045512.2:g.6211G>T;hgvs_aa=YP_009724389.1:p.Val2071Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6541	6541	.	+	.	ID=ID_48;Name=H2092H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=236;ao=10;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6276T;aa_name=p.H2092H;hgvs_nt=NC_045512.2:g.6276C>T;hgvs_aa=YP_009724389.1:p.His2092His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04065040650406504;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6613	6613	.	+	.	ID=ID_49;Name=V2116V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A6348G;aa_name=p.V2116V;hgvs_nt=NC_045512.2:g.6348A>G;hgvs_aa=YP_009724389.1:p.Val2116Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6627	6627	.	+	.	ID=ID_50;Name=T2121I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=210;ao=36;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6362T;aa_name=p.T2121I;hgvs_nt=NC_045512.2:g.6362C>T;hgvs_aa=YP_009724389.1:p.Thr2121Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.14634146341463414;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6762	6762	.	+	.	ID=ID_51;Name=T2166I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=238;ao=8;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6497T;aa_name=p.T2166I;hgvs_nt=NC_045512.2:g.6497C>T;hgvs_aa=YP_009724389.1:p.Thr2166Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.032520325203252036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6990	6990	.	+	.	ID=ID_52;Name=S2242F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=239;ao=7;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C6725T;aa_name=p.S2242F;hgvs_nt=NC_045512.2:g.6725C>T;hgvs_aa=YP_009724389.1:p.Ser2242Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028455284552845527;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7279	7279	.	+	.	ID=ID_53;Name=F2338F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=236;ao=10;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C7014T;aa_name=p.F2338F;hgvs_nt=NC_045512.2:g.7014C>T;hgvs_aa=YP_009724389.1:p.Phe2338Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04065040650406504;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7591	7591	.	+	.	ID=ID_54;Name=K2442K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A7326G;aa_name=p.K2442K;hgvs_nt=NC_045512.2:g.7326A>G;hgvs_aa=YP_009724389.1:p.Lys2442Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7712	7712	.	+	.	ID=ID_55;Name=P2483S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C7447T;aa_name=p.P2483S;hgvs_nt=NC_045512.2:g.7447C>T;hgvs_aa=YP_009724389.1:p.Pro2483Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7850	7850	.	+	.	ID=ID_56;Name=A2529T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G7585A;aa_name=p.A2529T;hgvs_nt=NC_045512.2:g.7585G>A;hgvs_aa=YP_009724389.1:p.Ala2529Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7979	7979	.	+	.	ID=ID_57;Name=L2572L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C7714T;aa_name=p.L2572L;hgvs_nt=NC_045512.2:g.7714C>T;hgvs_aa=YP_009724389.1:p.Leu2572Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8290	8290	.	+	.	ID=ID_58;Name=L2675L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C8025T;aa_name=p.L2675L;hgvs_nt=NC_045512.2:g.8025C>T;hgvs_aa=YP_009724389.1:p.Leu2675Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8622	8622	.	+	.	ID=ID_59;Name=I2786T;alias=I23T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T8357C;aa_name=p.I2786T;hgvs_nt=NC_045512.2:g.8357T>C;hgvs_aa=YP_009724389.1:p.Ile2786Thr;hgvs_alias=YP_009724389.1:Ile23Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8802	8802	.	+	.	ID=ID_60;Name=T2846I;alias=T83I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C8537T;aa_name=p.T2846I;hgvs_nt=NC_045512.2:g.8537C>T;hgvs_aa=YP_009724389.1:p.Thr2846Ile;hgvs_alias=YP_009724389.1:Thr83Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9086	9086	.	+	.	ID=ID_61;Name=G2941S;alias=G178S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G8821A;aa_name=p.G2941S;hgvs_nt=NC_045512.2:g.8821G>A;hgvs_aa=YP_009724389.1:p.Gly2941Ser;hgvs_alias=YP_009724389.1:Gly178Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9842	9842	.	+	.	ID=ID_62;Name=L3193L;alias=L430L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T9577C;aa_name=p.L3193L;hgvs_nt=NC_045512.2:g.9577T>C;hgvs_aa=YP_009724389.1:p.Leu3193Leu;hgvs_alias=YP_009724389.1:Leu430Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9857	9857	.	+	.	ID=ID_63;Name=L3198L;alias=L435L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C9592T;aa_name=p.L3198L;hgvs_nt=NC_045512.2:g.9592C>T;hgvs_aa=YP_009724389.1:p.Leu3198Leu;hgvs_alias=YP_009724389.1:Leu435Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10116	10116	.	+	.	ID=ID_64;Name=T3284I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=238;ao=7;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C9851T;aa_name=p.T3284I;hgvs_nt=NC_045512.2:g.9851C>T;hgvs_aa=YP_009724389.1:p.Thr3284Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02857142857142857;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10323	10323	.	+	.	ID=ID_65;Name=K3353R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=236;ao=10;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A10058G;aa_name=p.K3353R;hgvs_nt=NC_045512.2:g.10058A>G;hgvs_aa=YP_009724389.1:p.Lys3353Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04065040650406504;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10334	10334	.	+	.	ID=ID_66;Name=A3357T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=234;ao=12;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G10069A;aa_name=p.A3357T;hgvs_nt=NC_045512.2:g.10069G>A;hgvs_aa=YP_009724389.1:p.Ala3357Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04878048780487805;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10525	10525	.	+	.	ID=ID_67;Name=V3420V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C10260T;aa_name=p.V3420V;hgvs_nt=NC_045512.2:g.10260C>T;hgvs_aa=YP_009724389.1:p.Val3420Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10824	10824	.	+	.	ID=ID_68;Name=T3520I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=240;ao=2;dp=242;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C10559T;aa_name=p.T3520I;hgvs_nt=NC_045512.2:g.10559C>T;hgvs_aa=YP_009724389.1:p.Thr3520Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008264462809917356;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10983	10983	.	+	.	ID=ID_69;Name=K3573R;alias=K4R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=210;ao=33;dp=243;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A10718G;aa_name=p.K3573R;hgvs_nt=NC_045512.2:g.10718A>G;hgvs_aa=YP_009724389.1:p.Lys3573Arg;hgvs_alias=YP_009724389.1:Lys4Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13580246913580246;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_70;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11150	11150	.	+	.	ID=ID_71;Name=V3629I;alias=V60I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G10885A;aa_name=p.V3629I;hgvs_nt=NC_045512.2:g.10885G>A;hgvs_aa=YP_009724389.1:p.Val3629Ile;hgvs_alias=YP_009724389.1:Val60Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_72;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_72;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_72;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=P.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11339	11339	.	+	.	ID=ID_73;Name=L3692L;alias=L123L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=239;ao=7;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11074T;aa_name=p.L3692L;hgvs_nt=NC_045512.2:g.11074C>T;hgvs_aa=YP_009724389.1:p.Leu3692Leu;hgvs_alias=YP_009724389.1:Leu123Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028455284552845527;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11407	11407	.	+	.	ID=ID_74;Name=V3714V;alias=V145V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11142T;aa_name=p.V3714V;hgvs_nt=NC_045512.2:g.11142C>T;hgvs_aa=YP_009724389.1:p.Val3714Val;hgvs_alias=YP_009724389.1:Val145Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11750	11750	.	+	.	ID=ID_75;Name=L3829F;alias=L260F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=237;ao=6;dp=243;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11485T;aa_name=p.L3829F;hgvs_nt=NC_045512.2:g.11485C>T;hgvs_aa=YP_009724389.1:p.Leu3829Phe;hgvs_alias=YP_009724389.1:Leu260Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024691358024691357;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11752	11752	.	+	.	ID=ID_76;Name=L3829L;alias=L260L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11487T;aa_name=p.L3829L;hgvs_nt=NC_045512.2:g.11487C>T;hgvs_aa=YP_009724389.1:p.Leu3829Leu;hgvs_alias=YP_009724389.1:Leu260Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11812	11812	.	+	.	ID=ID_77;Name=G3849G;alias=G280G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11547T;aa_name=p.G3849G;hgvs_nt=NC_045512.2:g.11547C>T;hgvs_aa=YP_009724389.1:p.Gly3849Gly;hgvs_alias=YP_009724389.1:Gly280Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12020	12020	.	+	.	ID=ID_78;Name=L3919F;alias=L60F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C11755T;aa_name=p.L3919F;hgvs_nt=NC_045512.2:g.11755C>T;hgvs_aa=YP_009724389.1:p.Leu3919Phe;hgvs_alias=YP_009724389.1:Leu60Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12070	12070	.	+	.	ID=ID_79;Name=L3935L;alias=L76L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G11805T;aa_name=p.L3935L;hgvs_nt=NC_045512.2:g.11805G>T;hgvs_aa=YP_009724389.1:p.Leu3935Leu;hgvs_alias=YP_009724389.1:Leu76Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12121	12121	.	+	.	ID=ID_80;Name=P3952P;alias=P10P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=225;ao=21;dp=246;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A11856T;aa_name=p.P3952P;hgvs_nt=NC_045512.2:g.11856A>T;hgvs_aa=YP_009724389.1:p.Pro3952Pro;hgvs_alias=YP_009724389.1:Pro10Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08536585365853659;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12357	12357	.	+	.	ID=ID_81;Name=T4031I;alias=T89I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C12092T;aa_name=p.T4031I;hgvs_nt=NC_045512.2:g.12092C>T;hgvs_aa=YP_009724389.1:p.Thr4031Ile;hgvs_alias=YP_009724389.1:Thr89Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12439	12439	.	+	.	ID=ID_82;Name=P4058P;alias=P116P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C12174T;aa_name=p.P4058P;hgvs_nt=NC_045512.2:g.12174C>T;hgvs_aa=YP_009724389.1:p.Pro4058Pro;hgvs_alias=YP_009724389.1:Pro116Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12710	12710	.	+	.	ID=ID_83;Name=L4149L;alias=L9L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C12445T;aa_name=p.L4149L;hgvs_nt=NC_045512.2:g.12445C>T;hgvs_aa=YP_009724389.1:p.Leu4149Leu;hgvs_alias=YP_009724389.1:Leu9Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12778	12778	.	+	.	ID=ID_84;Name=Y4171Y;alias=Y31Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=2;ao=244;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C12513T;aa_name=p.Y4171Y;hgvs_nt=NC_045512.2:g.12513C>T;hgvs_aa=YP_009724389.1:p.Tyr4171Tyr;hgvs_alias=YP_009724389.1:Tyr31Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.991869918699187;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12784	12784	.	+	.	ID=ID_85;Name=N4173N;alias=N33N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=240;ao=6;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C12519T;aa_name=p.N4173N;hgvs_nt=NC_045512.2:g.12519C>T;hgvs_aa=YP_009724389.1:p.Asn4173Asn;hgvs_alias=YP_009724389.1:Asn33Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13348	13348	.	+	.	ID=ID_86;Name=V4361V;alias=V108V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G13083T;aa_name=p.V4361V;hgvs_nt=NC_045512.2:g.13083G>T;hgvs_aa=YP_009724389.1:p.Val4361Val;hgvs_alias=YP_009724389.1:Val108Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13711	13711	.	+	.	ID=ID_87;Name=K4483E;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A13447G;aa_name=p.K4483E;hgvs_nt=NC_045512.2:g.13447A>G;hgvs_aa=YP_009724389.1:p.Lys4483Glu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13860	13860	.	+	.	ID=ID_88;Name=D4532D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C13596T;aa_name=p.D4532D;hgvs_nt=NC_045512.2:g.13596C>T;hgvs_aa=YP_009724389.1:p.Asp4532Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13887	13887	.	+	.	ID=ID_89;Name=Y4541Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=239;ao=7;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C13623T;aa_name=p.Y4541Y;hgvs_nt=NC_045512.2:g.13623C>T;hgvs_aa=YP_009724389.1:p.Tyr4541Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028455284552845527;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13928	13928	.	+	.	ID=ID_90;Name=Y4555C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A13664G;aa_name=p.Y4555C;hgvs_nt=NC_045512.2:g.13664A>G;hgvs_aa=YP_009724389.1:p.Tyr4555Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_91;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14742	14742	.	+	.	ID=ID_92;Name=S4826S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=T;Variant_seq=A;nt_name=g.T14478A;aa_name=p.S4826S;hgvs_nt=NC_045512.2:g.14478T>A;hgvs_aa=YP_009724389.1:p.Ser4826Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15380	15380	.	+	.	ID=ID_93;Name=S5039I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G15116T;aa_name=p.S5039I;hgvs_nt=NC_045512.2:g.15116G>T;hgvs_aa=YP_009724389.1:p.Ser5039Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15672	15672	.	+	.	ID=ID_94;Name=E5136D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G15408T;aa_name=p.E5136D;hgvs_nt=NC_045512.2:g.15408G>T;hgvs_aa=YP_009724389.1:p.Glu5136Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15960	15960	.	+	.	ID=ID_95;Name=A5232A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=233;ao=13;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C15696T;aa_name=p.A5232A;hgvs_nt=NC_045512.2:g.15696C>T;hgvs_aa=YP_009724389.1:p.Ala5232Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.052845528455284556;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16260	16260	.	+	.	ID=ID_96;Name=C5332C;alias=C8C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=239;ao=7;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C15996T;aa_name=p.C5332C;hgvs_nt=NC_045512.2:g.15996C>T;hgvs_aa=YP_009724389.1:p.Cys5332Cys;hgvs_alias=YP_009724389.1:Cys8Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028455284552845527;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16289	16289	.	+	.	ID=ID_97;Name=A5342V;alias=A18V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C16025T;aa_name=p.A5342V;hgvs_nt=NC_045512.2:g.16025C>T;hgvs_aa=YP_009724389.1:p.Ala5342Val;hgvs_alias=YP_009724389.1:Ala18Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16356	16356	.	+	.	ID=ID_98;Name=K5364K;alias=K40K;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A16092G;aa_name=p.K5364K;hgvs_nt=NC_045512.2:g.16092A>G;hgvs_aa=YP_009724389.1:p.Lys5364Lys;hgvs_alias=YP_009724389.1:Lys40Lys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16887	16887	.	+	.	ID=ID_99;Name=Y5541Y;alias=Y217Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=233;ao=13;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C16623T;aa_name=p.Y5541Y;hgvs_nt=NC_045512.2:g.16623C>T;hgvs_aa=YP_009724389.1:p.Tyr5541Tyr;hgvs_alias=YP_009724389.1:Tyr217Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.052845528455284556;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17000	17000	.	+	.	ID=ID_100;Name=T5579I;alias=T255I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C16736T;aa_name=p.T5579I;hgvs_nt=NC_045512.2:g.16736C>T;hgvs_aa=YP_009724389.1:p.Thr5579Ile;hgvs_alias=YP_009724389.1:Thr255Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17004	17004	.	+	.	ID=ID_101;Name=L5580L;alias=L256L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C16740T;aa_name=p.L5580L;hgvs_nt=NC_045512.2:g.16740C>T;hgvs_aa=YP_009724389.1:p.Leu5580Leu;hgvs_alias=YP_009724389.1:Leu256Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17110	17110	.	+	.	ID=ID_102;Name=A5616S;alias=A292S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G16846T;aa_name=p.A5616S;hgvs_nt=NC_045512.2:g.16846G>T;hgvs_aa=YP_009724389.1:p.Ala5616Ser;hgvs_alias=YP_009724389.1:Ala292Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17122	17122	.	+	.	ID=ID_103;Name=A5620S;alias=A296S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G16858T;aa_name=p.A5620S;hgvs_nt=NC_045512.2:g.16858G>T;hgvs_aa=YP_009724389.1:p.Ala5620Ser;hgvs_alias=YP_009724389.1:Ala296Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17259	17259	.	+	.	ID=ID_104;Name=E5665D;alias=E341D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=2;ao=244;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G16995T;aa_name=p.E5665D;hgvs_nt=NC_045512.2:g.16995G>T;hgvs_aa=YP_009724389.1:p.Glu5665Asp;hgvs_alias=YP_009724389.1:Glu341Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.991869918699187;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17392	17392	.	+	.	ID=ID_105;Name=V5710F;alias=V386F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G17128T;aa_name=p.V5710F;hgvs_nt=NC_045512.2:g.17128G>T;hgvs_aa=YP_009724389.1:p.Val5710Phe;hgvs_alias=YP_009724389.1:Val386Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17745	17745	.	+	.	ID=ID_106;Name=N5827N;alias=N503N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=240;ao=6;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C17481T;aa_name=p.N5827N;hgvs_nt=NC_045512.2:g.17481C>T;hgvs_aa=YP_009724389.1:p.Asn5827Asn;hgvs_alias=YP_009724389.1:Asn503Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17746	17746	.	+	.	ID=ID_107;Name=P5828S;alias=P504S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C17482T;aa_name=p.P5828S;hgvs_nt=NC_045512.2:g.17482C>T;hgvs_aa=YP_009724389.1:p.Pro5828Ser;hgvs_alias=YP_009724389.1:Pro504Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17761	17761	.	+	.	ID=ID_108;Name=A5833S;alias=A509S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G17497T;aa_name=p.A5833S;hgvs_nt=NC_045512.2:g.17497G>T;hgvs_aa=YP_009724389.1:p.Ala5833Ser;hgvs_alias=YP_009724389.1:Ala509Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17988	17988	.	+	.	ID=ID_109;Name=K5908N;alias=K584N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G17724T;aa_name=p.K5908N;hgvs_nt=NC_045512.2:g.17724G>T;hgvs_aa=YP_009724389.1:p.Lys5908Asn;hgvs_alias=YP_009724389.1:Lys584Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17999	17999	.	+	.	ID=ID_110;Name=T5912I;alias=T588I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C17735T;aa_name=p.T5912I;hgvs_nt=NC_045512.2:g.17735C>T;hgvs_aa=YP_009724389.1:p.Thr5912Ile;hgvs_alias=YP_009724389.1:Thr588Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18085	18085	.	+	.	ID=ID_111;Name=T5941A;alias=T16A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A17821G;aa_name=p.T5941A;hgvs_nt=NC_045512.2:g.17821A>G;hgvs_aa=YP_009724389.1:p.Thr5941Ala;hgvs_alias=YP_009724389.1:Thr16Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18181	18181	.	+	.	ID=ID_112;Name=D5973N;alias=D48N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G17917A;aa_name=p.D5973N;hgvs_nt=NC_045512.2:g.17917G>A;hgvs_aa=YP_009724389.1:p.Asp5973Asn;hgvs_alias=YP_009724389.1:Asp48Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18348	18348	.	+	.	ID=ID_113;Name=T6028T;alias=T103T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C18084T;aa_name=p.T6028T;hgvs_nt=NC_045512.2:g.18084C>T;hgvs_aa=YP_009724389.1:p.Thr6028Thr;hgvs_alias=YP_009724389.1:Thr103Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18651	18651	.	+	.	ID=ID_114;Name=E6129D;alias=E204D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G18387T;aa_name=p.E6129D;hgvs_nt=NC_045512.2:g.18387G>T;hgvs_aa=YP_009724389.1:p.Glu6129Asp;hgvs_alias=YP_009724389.1:Glu204Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19326	19326	.	+	.	ID=ID_115;Name=P6354P;alias=P429P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=230;ao=2;dp=232;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A19062G;aa_name=p.P6354P;hgvs_nt=NC_045512.2:g.19062A>G;hgvs_aa=YP_009724389.1:p.Pro6354Pro;hgvs_alias=YP_009724389.1:Pro429Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008620689655172414;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19955	19955	.	+	.	ID=ID_116;Name=T6564I;alias=T112I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=234;ao=12;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C19691T;aa_name=p.T6564I;hgvs_nt=NC_045512.2:g.19691C>T;hgvs_aa=YP_009724389.1:p.Thr6564Ile;hgvs_alias=YP_009724389.1:Thr112Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04878048780487805;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19965	19965	.	+	.	ID=ID_117;Name=I6567I;alias=I115I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T19701C;aa_name=p.I6567I;hgvs_nt=NC_045512.2:g.19701T>C;hgvs_aa=YP_009724389.1:p.Ile6567Ile;hgvs_alias=YP_009724389.1:Ile115Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20078	20078	.	+	.	ID=ID_118;Name=P6605L;alias=P153L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C19814T;aa_name=p.P6605L;hgvs_nt=NC_045512.2:g.19814C>T;hgvs_aa=YP_009724389.1:p.Pro6605Leu;hgvs_alias=YP_009724389.1:Pro153Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20234	20234	.	+	.	ID=ID_119;Name=P6657L;alias=P205L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C19970T;aa_name=p.P6657L;hgvs_nt=NC_045512.2:g.19970C>T;hgvs_aa=YP_009724389.1:p.Pro6657Leu;hgvs_alias=YP_009724389.1:Pro205Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20931	20931	.	+	.	ID=ID_120;Name=T6889T;alias=T91T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=211;ao=2;dp=213;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G20667A;aa_name=p.T6889T;hgvs_nt=NC_045512.2:g.20667G>A;hgvs_aa=YP_009724389.1:p.Thr6889Thr;hgvs_alias=YP_009724389.1:Thr91Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009389671361502348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	"ID=ID_121;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S;function_description=The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_122;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	"ID=ID_124;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_124;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_125;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_126;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_126;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_124;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_128;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1;citation=Ribas Freitas et al. (2021);comb_mutation=K417T,E484K,N501Y,H655Y;function_description=In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_128;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation=K417T,E484K,N501Y,H655Y;function_description=On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_128;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1;citation=Santos de Oliviera et al. (2021);comb_mutation=K417T,E484K,N501Y,H655Y;function_description=In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_122;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	"ID=ID_124;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_124;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_129;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_125;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_126;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_127;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_122;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_130;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_130;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_130;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_123;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_122;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_126;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_125;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_126;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	"ID=ID_121;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S;function_description=The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_122;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_131;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_126;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_126;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_122;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_129;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_131;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_126;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_127;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_122;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_130;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_130;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_130;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_123;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_122;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_126;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_131;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21621	21621	.	+	.	ID=ID_126;Name=T20N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=C;Variant_seq=A;nt_name=g.C59A;aa_name=p.T20N;hgvs_nt=NC_045512.2:g.59C>A;hgvs_aa=YP_009724390.1:p.Thr20Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	"ID=ID_121;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S;function_description=The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_122;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_132;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_126;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_126;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_122;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_129;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_132;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_126;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_127;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_122;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_130;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_130;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_130;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_123;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_122;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_126;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_132;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_126;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21770	21770	.	+	.	ID=ID_133;Name=V70F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G208T;aa_name=p.V70F;hgvs_nt=NC_045512.2:g.208G>T;hgvs_aa=YP_009724390.1:p.Val70Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21920	21920	.	+	.	ID=ID_134;Name=V120L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=G;Variant_seq=C;nt_name=g.G358C;aa_name=p.V120L;hgvs_nt=NC_045512.2:g.358G>C;hgvs_aa=YP_009724390.1:p.Val120Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	"ID=ID_121;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=L18F,T20N,P26S,R190S;function_description=The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_122;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_135;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_126;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_126;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_122;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_129;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,E484K,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_135;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_126;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_127;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_122;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_130;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_130;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_130;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_123;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_122;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_136;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_126;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_135;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_126;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22088	22088	.	+	.	ID=ID_137;Name=L176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=219;ao=4;dp=223;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C526T;aa_name=p.L176F;hgvs_nt=NC_045512.2:g.526C>T;hgvs_aa=YP_009724390.1:p.Leu176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017937219730941704;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22104	22104	.	+	.	ID=ID_138;Name=G181V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=222;ao=3;dp=225;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G542T;aa_name=p.G181V;hgvs_nt=NC_045512.2:g.542G>T;hgvs_aa=YP_009724390.1:p.Gly181Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	"ID=ID_121;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y;function_description=The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_122;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_139;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_126;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_126;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_122;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_129;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,E484K,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_139;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_126;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_127;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_122;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_130;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_130;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_130;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_123;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_122;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_140;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_126;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_139;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22132	22132	.	+	.	ID=ID_126;Name=R190S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=224;dp=224;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G570T;aa_name=p.R190S;hgvs_nt=NC_045512.2:g.570G>T;hgvs_aa=YP_009724390.1:p.Arg190Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22240	22240	.	+	.	ID=ID_141;Name=L226L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=210;ao=3;dp=213;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G678A;aa_name=p.L226L;hgvs_nt=NC_045512.2:g.678G>A;hgvs_aa=YP_009724390.1:p.Leu226Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014084507042253521;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22289	22289	.	+	.	ID=ID_142;Name=A243S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=198;ao=1;dp=199;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G727T;aa_name=p.A243S;hgvs_nt=NC_045512.2:g.727G>T;hgvs_aa=YP_009724390.1:p.Ala243Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005025125628140704;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22323	22323	.	+	.	"ID=ID_143;Name=S254F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=240;ao=2;dp=242;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C761T;aa_name=p.S254F;hgvs_nt=NC_045512.2:g.761C>T;hgvs_aa=YP_009724390.1:p.Ser254Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008264462809917356;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies.;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22456	22456	.	+	.	ID=ID_144;Name=E298E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=226;ao=18;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A894G;aa_name=p.E298E;hgvs_nt=NC_045512.2:g.894A>G;hgvs_aa=YP_009724390.1:p.Glu298Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07377049180327869;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22687	22687	.	+	.	ID=ID_145;Name=S375S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=2;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1125T;aa_name=p.S375S;hgvs_nt=NC_045512.2:g.1125C>T;hgvs_aa=YP_009724390.1:p.Ser375Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00819672131147541;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22696	22696	.	+	.	ID=ID_146;Name=K378N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=220;ao=24;dp=244;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1134T;aa_name=p.K378N;hgvs_nt=NC_045512.2:g.1134G>T;hgvs_aa=YP_009724390.1:p.Lys378Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.09836065573770492;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22729	22729	.	+	.	ID=ID_147;Name=D389D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=241;ao=3;dp=244;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T1167C;aa_name=p.D389D;hgvs_nt=NC_045512.2:g.1167T>C;hgvs_aa=YP_009724390.1:p.Asp389Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012295081967213115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_122;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_148;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_126;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_150;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=E484K,N501Y;function_description=The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_151;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_126;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_150;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K,N501Y;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~16x binding against this isolated mutation. Estesevimab lost ~16x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_128;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1;citation=Ribas Freitas et al. (2021);comb_mutation=L18F,E484K,N501Y,H655Y;function_description=In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_128;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation=L18F,E484K,N501Y,H655Y;function_description=On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_128;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1;citation=Santos de Oliviera et al. (2021);comb_mutation=L18F,E484K,N501Y,H655Y;function_description=In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_122;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_148;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_126;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_127;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_122;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_130;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_130;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_130;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_123;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 antibody C682;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.25 fold;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_122;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_149;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_126;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_148;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22812	22812	.	+	.	ID=ID_126;Name=K417T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=A;Variant_seq=C;nt_name=g.A1250C;aa_name=p.K417T;hgvs_nt=NC_045512.2:g.1250A>C;hgvs_aa=YP_009724390.1:p.Lys417Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22841	22841	.	+	.	ID=ID_152;Name=D427N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=234;ao=10;dp=244;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1279A;aa_name=p.D427N;hgvs_nt=NC_045512.2:g.1279G>A;hgvs_aa=YP_009724390.1:p.Asp427Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040983606557377046;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22906	22906	.	+	.	ID=ID_153;Name=N448N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=230;ao=11;dp=241;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T1344C;aa_name=p.N448N;hgvs_nt=NC_045512.2:g.1344T>C;hgvs_aa=YP_009724390.1:p.Asn448Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04564315352697095;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22945	22945	.	+	.	ID=ID_154;Name=L461L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=210;ao=32;dp=242;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1383T;aa_name=p.L461L;hgvs_nt=NC_045512.2:g.1383C>T;hgvs_aa=YP_009724390.1:p.Leu461Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1322314049586777;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22960	22960	.	+	.	ID=ID_155;Name=R466R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=7;dp=242;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1398G;aa_name=p.R466R;hgvs_nt=NC_045512.2:g.1398A>G;hgvs_aa=YP_009724390.1:p.Arg466Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028925619834710745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_158;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=N501Y;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_150;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=K417T,N501Y;function_description=The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_151;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=K417T,N501Y,D614G;function_description=The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_158;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_158;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_158;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_150;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417T,N501Y;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_128;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1;citation=Ribas Freitas et al. (2021);comb_mutation=L18F,K417T,N501Y,H655Y;function_description=In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_128;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation=L18F,K417T,N501Y,H655Y;function_description=On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_128;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1;citation=Santos de Oliviera et al. (2021);comb_mutation=L18F,K417T,N501Y,H655Y;function_description=In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_129;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,N501Y,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_158;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_127;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_160;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=D614G,V1176F;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_130;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_130;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_130;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_157;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=N501Y;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_156;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_159;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=241;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958677685950413;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_122;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_126;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=E484K;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_150;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=K417T,E484K;function_description=The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_151;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=K417T,E484K,D614G;function_description=The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_126;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_150;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417T,E484K;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1;citation=Ribas Freitas et al. (2021);comb_mutation=L18F,K417T,E484K,H655Y;function_description=In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation=L18F,K417T,E484K,H655Y;function_description=On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1;citation=Santos de Oliviera et al. (2021);comb_mutation=L18F,K417T,E484K,H655Y;function_description=In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_122;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_129;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,D614G,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_126;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_122;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_130;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_130;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_130;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=E484K;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_122;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_161;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_126;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,D614G,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_162;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_126;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=242;dp=243;sample_size=288;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9958847736625515;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23260	23260	.	+	.	ID=ID_163;Name=G566G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=2;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1698T;aa_name=p.G566G;hgvs_nt=NC_045512.2:g.1698C>T;hgvs_aa=YP_009724390.1:p.Gly566Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00819672131147541;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23380	23380	.	+	.	ID=ID_164;Name=N606N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=240;ao=4;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1818T;aa_name=p.N606N;hgvs_nt=NC_045512.2:g.1818C>T;hgvs_aa=YP_009724390.1:p.Asn606Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01639344262295082;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_122;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T20N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_135;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_139;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=R190S;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417T;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_166;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_167;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_151;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2021.03.055;citation=Dejnirattisai et al. (2021);comb_mutation=K417T,E484K,N501Y;function_description=The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_122;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_129;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,H655Y;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T20N;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_135;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_139;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=R190S;function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417T;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_166;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_167;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T1027I;function_description=1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_160;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=E484K,V1176F;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_122;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_123;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_165;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_122;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_159;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T20N;function_description=1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_135;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_139;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=R190S;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_148;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417T;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_166;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_167;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T1027I;function_description=1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=244;dp=244;sample_size=288;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_168;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_122;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=antibody epitope effects;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G;function_description=Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_166;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_126;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_126;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_128;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1;citation=Ribas Freitas et al. (2021);comb_mutation=L18F,K417T,E484K,N501Y;function_description=In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI ;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_128;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation=L18F,K417T,E484K,N501Y;function_description=On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_128;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1;citation=Santos de Oliviera et al. (2021);comb_mutation=L18F,K417T,E484K,N501Y;function_description=In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_168;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_122;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G;function_description=In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_129;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1;citation=Stefanelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,E484K,N501Y,D614G;function_description=The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_166;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_126;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_127;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_122;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G;function_description=In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_130;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_130;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_130;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_123;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_122;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=virion structure;source=https://dx.doi.org/10.1101%2F2021.03.01.433466;citation=Wang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G;function_description=CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_168;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_126;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,T1027I;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_166;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_126;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=243;dp=244;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959016393442623;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,T1027I;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23611	23611	.	+	.	ID=ID_169;Name=R683R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=5;dp=240;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G2049T;aa_name=p.R683R;hgvs_nt=NC_045512.2:g.2049G>T;hgvs_aa=YP_009724390.1:p.Arg683Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020833333333333332;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23625	23625	.	+	.	ID=ID_170;Name=A688V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=234;ao=5;dp=239;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2063T;aa_name=p.A688V;hgvs_nt=NC_045512.2:g.2063C>T;hgvs_aa=YP_009724390.1:p.Ala688Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02092050209205021;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23896	23896	.	+	.	ID=ID_171;Name=T778T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=238;ao=2;dp=240;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2334T;aa_name=p.T778T;hgvs_nt=NC_045512.2:g.2334C>T;hgvs_aa=YP_009724390.1:p.Thr778Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23934	23934	.	+	.	ID=ID_172;Name=T791I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=238;ao=2;dp=240;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2372T;aa_name=p.T791I;hgvs_nt=NC_045512.2:g.2372C>T;hgvs_aa=YP_009724390.1:p.Thr791Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23997	23997	.	+	.	ID=ID_173;Name=P812L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=236;ao=3;dp=239;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C2435T;aa_name=p.P812L;hgvs_nt=NC_045512.2:g.2435C>T;hgvs_aa=YP_009724390.1:p.Pro812Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012552301255230125;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_167;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_126;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_126;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_167;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_126;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_127;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,V1176F;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_130;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_130;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1;citation=Andrade et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_130;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1;citation=Hitchlings et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_123;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,V1176F;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_174;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_126;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1590/s1678-9946202163036;citation=Malta Romano et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y;function_description=After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_167;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24642	24642	.	+	.	ID=ID_126;Name=T1027I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=237;dp=237;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C3080T;aa_name=p.T1027I;hgvs_nt=NC_045512.2:g.3080C>T;hgvs_aa=YP_009724390.1:p.Thr1027Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y;function_description=This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25027	25027	.	+	.	ID=ID_175;Name=Y1155Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=237;ao=7;dp=244;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T3465C;aa_name=p.Y1155Y;hgvs_nt=NC_045512.2:g.3465T>C;hgvs_aa=YP_009724390.1:p.Tyr1155Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028688524590163935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=trafficking;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1;citation=Montagutelli et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://doi.org/10.1056/nejmc2104036;citation=Luftig et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1;citation=Mendes-Correa et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in];heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.036;citation=Hoffman et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_127;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I;function_description=1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_160;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=E484K,D614G;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1;citation=Leier et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_123;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=244;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959183673469387;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I;function_description=The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4);heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25413	25413	.	+	.	ID=ID_176;Name=I7I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=221;ao=24;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C21T;aa_name=p.I7I;hgvs_nt=NC_045512.2:g.21C>T;hgvs_aa=YP_009724391.1:p.Ile7Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.09795918367346938;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25427	25427	.	+	.	ID=ID_177;Name=T12I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=238;ao=7;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C35T;aa_name=p.T12I;hgvs_nt=NC_045512.2:g.35C>T;hgvs_aa=YP_009724391.1:p.Thr12Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02857142857142857;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25455	25455	.	+	.	ID=ID_178;Name=K21N;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=238;ao=7;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G63T;aa_name=p.K21N;hgvs_nt=NC_045512.2:g.63G>T;hgvs_aa=YP_009724391.1:p.Lys21Asn;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02857142857142857;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25469	25469	.	+	.	ID=ID_179;Name=S26L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C77T;aa_name=p.S26L;hgvs_nt=NC_045512.2:g.77C>T;hgvs_aa=YP_009724391.1:p.Ser26Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_180;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=241;ao=4;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0163265306122449;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25688	25688	.	+	.	ID=ID_181;Name=A99V;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C296T;aa_name=p.A99V;hgvs_nt=NC_045512.2:g.296C>T;hgvs_aa=YP_009724391.1:p.Ala99Val;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25710	25710	.	+	.	ID=ID_182;Name=L106L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C318T;aa_name=p.L106L;hgvs_nt=NC_045512.2:g.318C>T;hgvs_aa=YP_009724391.1:p.Leu106Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25839	25839	.	+	.	ID=ID_183;Name=W149C;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G447T;aa_name=p.W149C;hgvs_nt=NC_045512.2:g.447G>T;hgvs_aa=YP_009724391.1:p.Trp149Cys;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25904	25904	.	+	.	ID=ID_184;Name=S171L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C512T;aa_name=p.S171L;hgvs_nt=NC_045512.2:g.512C>T;hgvs_aa=YP_009724391.1:p.Ser171Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25963	25963	.	+	.	ID=ID_185;Name=E191Q;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=G;Variant_seq=C;nt_name=g.G571C;aa_name=p.E191Q;hgvs_nt=NC_045512.2:g.571G>C;hgvs_aa=YP_009724391.1:p.Glu191Gln;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26149	26149	.	+	.	ID=ID_186;Name=S253P;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=T;Variant_seq=C;nt_name=g.T757C;aa_name=p.S253P;hgvs_nt=NC_045512.2:g.757T>C;hgvs_aa=YP_009724391.1:p.Ser253Pro;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26165	26165	.	+	.	ID=ID_187;Name=P258L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C773T;aa_name=p.P258L;hgvs_nt=NC_045512.2:g.773C>T;hgvs_aa=YP_009724391.1:p.Pro258Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26660	26660	.	+	.	ID=ID_188;Name=L46F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G138T;aa_name=p.L46F;hgvs_nt=NC_045512.2:g.138G>T;hgvs_aa=YP_009724393.1:p.Leu46Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27005	27005	.	+	.	ID=ID_189;Name=I161I;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C483T;aa_name=p.I161I;hgvs_nt=NC_045512.2:g.483C>T;hgvs_aa=YP_009724393.1:p.Ile161Ile;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27059	27059	.	+	.	ID=ID_190;Name=Y179Y;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C537T;aa_name=p.Y179Y;hgvs_nt=NC_045512.2:g.537C>T;hgvs_aa=YP_009724393.1:p.Tyr179Tyr;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27371	27371	.	+	.	ID=ID_191;Name=P57L;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C170T;aa_name=p.P57L;hgvs_nt=NC_045512.2:g.170C>T;hgvs_aa=YP_009724394.1:p.Pro57Leu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27600	27600	.	+	.	ID=ID_192;Name=D69D;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=240;ao=5;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C207T;aa_name=p.D69D;hgvs_nt=NC_045512.2:g.207C>T;hgvs_aa=YP_009724395.1:p.Asp69Asp;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02040816326530612;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27621	27621	.	+	.	ID=ID_193;Name=Q76H;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G228T;aa_name=p.Q76H;hgvs_nt=NC_045512.2:g.228G>T;hgvs_aa=YP_009724395.1:p.Gln76His;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27679	27679	.	+	.	ID=ID_194;Name=L96F;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=3;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C286T;aa_name=p.L96F;hgvs_nt=NC_045512.2:g.286C>T;hgvs_aa=YP_009724395.1:p.Leu96Phe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012244897959183673;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27689	27689	.	+	.	ID=ID_195;Name=P99L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C296T;aa_name=p.P99L;hgvs_nt=NC_045512.2:g.296C>T;hgvs_aa=YP_009724395.1:p.Pro99Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27707	27707	.	+	.	ID=ID_196;Name=A105V;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C314T;aa_name=p.A105V;hgvs_nt=NC_045512.2:g.314C>T;hgvs_aa=YP_009724395.1:p.Ala105Val;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28077	28077	.	+	.	ID=ID_197;Name=V62L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=226;ao=2;dp=228;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G184T;aa_name=p.V62L;hgvs_nt=NC_045512.2:g.184G>T;hgvs_aa=YP_009724396.1:p.Val62Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008771929824561403;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28093	28093	.	+	.	ID=ID_198;Name=S67F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=219;ao=4;dp=223;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C200T;aa_name=p.S67F;hgvs_nt=NC_045512.2:g.200C>T;hgvs_aa=YP_009724396.1:p.Ser67Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017937219730941704;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28167	28167	.	+	.	ID=ID_199;Name=E92K;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=245;dp=246;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G274A;aa_name=p.E92K;hgvs_nt=NC_045512.2:g.274G>A;hgvs_aa=YP_009724396.1:p.Glu92Lys;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9959349593495935;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	ins	28262	28262	.	+	.	ID=ID_200;Name=g.-12_-11insAACA;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=G;Variant_seq=GAACA;nt_name=g.-12_-11insAACA;aa_name=;hgvs_nt=NC_045512.2:g.-12_-11insAACA;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28371	28371	.	+	.	ID=ID_201;Name=S33I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G98T;aa_name=p.S33I;hgvs_nt=NC_045512.2:g.98G>T;hgvs_aa=YP_009724397.2:p.Ser33Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28378	28378	.	+	.	ID=ID_202;Name=A35A;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=196;ao=50;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G105T;aa_name=p.A35A;hgvs_nt=NC_045512.2:g.105G>T;hgvs_aa=YP_009724397.2:p.Ala35Ala;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28395	28395	.	+	.	ID=ID_203;Name=R41L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G122T;aa_name=p.R41L;hgvs_nt=NC_045512.2:g.122G>T;hgvs_aa=YP_009724397.2:p.Arg41Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28512	28512	.	+	.	ID=ID_204;Name=P80R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=246;dp=246;sample_size=288;Reference_seq=C;Variant_seq=G;nt_name=g.C239G;aa_name=p.P80R;hgvs_nt=NC_045512.2:g.239C>G;hgvs_aa=YP_009724397.2:p.Pro80Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28541	28541	.	+	.	ID=ID_205;Name=A90S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=3;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G268T;aa_name=p.A90S;hgvs_nt=NC_045512.2:g.268G>T;hgvs_aa=YP_009724397.2:p.Ala90Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012195121951219513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	28877	28877	.	+	.	ID=ID_206;Name=RG203KR;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=245;dp=245;sample_size=288;Reference_seq=AGTAGGG;Variant_seq=TCTAAAC;nt_name=g.AGTAGGG604_610TCTAAAC;aa_name=p.RG203KR;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.ArgGly203LysArg;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28957	28957	.	+	.	ID=ID_207;Name=N228N;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=244;ao=2;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C684T;aa_name=p.N228N;hgvs_nt=NC_045512.2:g.684C>T;hgvs_aa=YP_009724397.2:p.Asn228Asn;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008130081300813009;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29171	29171	.	+	.	ID=ID_208;Name=H300Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C898T;aa_name=p.H300Y;hgvs_nt=NC_045512.2:g.898C>T;hgvs_aa=YP_009724397.2:p.His300Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29372	29372	.	+	.	ID=ID_209;Name=E367Q;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=11;dp=246;sample_size=288;Reference_seq=G;Variant_seq=C;nt_name=g.G1099C;aa_name=p.E367Q;hgvs_nt=NC_045512.2:g.1099G>C;hgvs_aa=YP_009724397.2:p.Glu367Gln;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044715447154471545;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29402	29402	.	+	.	ID=ID_210;Name=D377Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=239;ao=6;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1129T;aa_name=p.D377Y;hgvs_nt=NC_045512.2:g.1129G>T;hgvs_aa=YP_009724397.2:p.Asp377Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024489795918367346;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29422	29422	.	+	.	ID=ID_211;Name=P383P;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=240;ao=4;dp=244;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G1149A;aa_name=p.P383P;hgvs_nt=NC_045512.2:g.1149G>A;hgvs_aa=YP_009724397.2:p.Pro383Pro;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01639344262295082;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29474	29474	.	+	.	ID=ID_212;Name=D401Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=243;ao=2;dp=245;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1201T;aa_name=p.D401Y;hgvs_nt=NC_045512.2:g.1201G>T;hgvs_aa=YP_009724397.2:p.Asp401Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00816326530612245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29477	29477	.	+	.	ID=ID_213;Name=D402Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=8;dp=243;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1204T;aa_name=p.D402Y;hgvs_nt=NC_045512.2:g.1204G>T;hgvs_aa=YP_009724397.2:p.Asp402Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03292181069958848;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29511	29511	.	+	.	ID=ID_214;Name=S413I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=241;ao=5;dp=246;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G1238T;aa_name=p.S413I;hgvs_nt=NC_045512.2:g.1238G>T;hgvs_aa=YP_009724397.2:p.Ser413Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02032520325203252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29545	29545	.	+	.	ID=ID_215;Name=g.C-13T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=242;ao=4;dp=246;sample_size=288;Reference_seq=C;Variant_seq=T;nt_name=g.C-13T;aa_name=;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016260162601626018;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29692	29692	.	+	.	ID=ID_216;Name=g.G29692T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=241;ao=2;dp=243;sample_size=288;Reference_seq=G;Variant_seq=T;nt_name=g.G29692T;aa_name=;hgvs_nt=NC_045512.2:g.29692G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00823045267489712;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29742	29742	.	+	.	ID=ID_217;Name=g.G29742A;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=240;ao=2;dp=242;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G29742A;aa_name=;hgvs_nt=NC_045512.2:g.29742G>A;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008264462809917356;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29764	29764	.	+	.	ID=ID_218;Name=g.G29764A;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=214;ao=25;dp=239;sample_size=288;Reference_seq=G;Variant_seq=A;nt_name=g.G29764A;aa_name=;hgvs_nt=NC_045512.2:g.29764G>A;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=P.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10460251046025104;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Gamma;variant_type=VOC;voi_designation_date=;voc_designation_date=11-Jan-2021;vum_designation_date=;status=de_escalated;
